Compare Carvana Co (CVNA) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Regeneron Pharmaceuticals Inc — how do they compare? Carvana Co trades at $63.6 (market cap $69.07B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Carvana Co and Regeneron Pharmaceuticals Inc are close in size by market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Carvana Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| CVNA | REGN | |
|---|---|---|
Market Cap | $69.07B | $76.40B |
Volume | 6,556,641 | 626,381 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $852.03 |
52-Week Low | $56.27 | $557.73 |
Typical Hold Time | 28 Days | 107 Days |
Enterprise Value | $71.55B | $71.12B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $63.21, down 1.02% on the day, with a bearish technical signal from moving averages. The company reported strong fundamentals, including Q2 2026 EPS of $0.42 beating estimates, revenue growth to $20.32B in 2025, and a net income margin of 6.26%. Recent news highlights robust sales performance, with Jefferies noting September unit sales 40% above estimates. Cash flow trends show positive operational growth, though high debt levels and an elevated EV/EBITDA of 503.9 pose concerns.
The outlook for CVNA is mixed; strong revenue growth and operational improvements support upside potential, with a consensus price target of $84.07 implying significant appreciation. However, risks include high valuation multiples, substantial long-term debt of $5.26B, and bearish technical indicators. Investors should weigh robust earnings beats against volatility and leverage concerns.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
